Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer

Fig. 1

PD is a potential therapeutic treatment for TNBC. a Analysis of 171 tumours from the TCGA database showing mutations of genes in the CDK4/6 pathway. b The mRNA expression of RB in different breast cancer cell lines. c Cell cycle analysis of MDA-MB-231 cells treated with PD for 24 h. d MDA-MB-231 cells were treated with PD for 24 h, 48 h, or 72 h. e MDA-MB-231 cells were treated with PD for 48 h, after which PD was withdrawn for 24 h, 48 h, or 72 h. Changes in the cell cycle were observed by flow cytometry. Student’s t-test (two-tailed, equal variance) was used to derive P values: *P < 0.05, **P < 0.01, ***P < 0.001

Back to article page